Search research articles
Contact Us
Filters
Showing results (1-10 of 4) with videos related to
Page
of 1
Sort By:
International Journal of Speech Technology
|
April 3, 2023
Plain-to-clear speech video conversion for enhanced intelligibility
Shubam Sachdeva, Haoyao Ruan, Ghassan Hamarneh, et al.
Journal of Comparative Effectiveness Research
|
April 4, 2024
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer
Alessandria Struebing, Chelsea McKibbon, Haoyao Ruan, et al.
Advances in Therapy
|
July 25, 2022
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
Jianming He, Heather Berringer, Bart Heeg, et al.
Advances in Therapy
|
July 3, 2024
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Maria De Santis, Sara Martínez Breijo, Paul Robinson, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 4) with videos related to
Sort By:
Page
of 1
International Journal of Speech Technology
|
April 3, 2023
Plain-to-clear speech video conversion for enhanced intelligibility
Shubam Sachdeva, Haoyao Ruan, Ghassan Hamarneh, et al.
Journal of Comparative Effectiveness Research
|
April 4, 2024
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer
Alessandria Struebing, Chelsea McKibbon, Haoyao Ruan, et al.
Advances in Therapy
|
July 25, 2022
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
Jianming He, Heather Berringer, Bart Heeg, et al.
Advances in Therapy
|
July 3, 2024
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Maria De Santis, Sara Martínez Breijo, Paul Robinson, et al.
Page
of 1